Raj Kannan, Aerie Pharmaceuticals CEO
August 23, 2022 07:28 AM EDTUpdated 07:40 AM
Deals
R&D

Al­con, No­var­tis' for­mer eye dis­ease unit, con­tin­ues deal­mak­ing spree with $770M Aerie ac­qui­si­tion

Max Gelman

Senior Editor

Af­ter pick­ing up two drugs from a Bob Langer spin­out in a deal ear­li­er this year, Al­con is stay­ing busy.

The for­mer No­var­tis sub­sidiary fo­cused …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times